clinical trial · NCT00607711
Study of Oral Palifosfamide Tris in Solid Tumors
Alaunos Therapeutics·phase1·withdrawn
Advanced Canceroral palifosfamide tris
brief summary
The study of maximum tolerated dose and safety of oral palifosfamide tris capsules in advanced, refractory, solid tumors
started
Mar 1, 2008
primary completion
Nov 1, 2009
completion
Nov 1, 2009
last updated
Sep 29, 2026
official title
A Phase I Study of Oral Palifosfamide Tris in Advanced, Refractory, Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol